```html

Juvenile Primary Sclerosing Cholangitis (PSC)

Overview

Primary sclerosing cholangitis (PSC) is a chronic, progressive disease that causes inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. When the condition first appears in children or adolescents—typically before age 18—it is referred to as **Juvenile Primary Sclerosing Cholangitis**.

• Who it affects: Boys are slightly more often affected than girls (about 60% male). It frequently co‑exists with inflammatory bowel disease (IBD), especially ulcerative colitis.
• Prevalence: PSC is rare, occurring in roughly 0.5–1.5 per 100,000 children worldwide. In pediatric IBD cohorts, up to 5–10% have concurrent PSC.
• Course of disease: The disorder progresses over years, eventually leading to cholestasis, biliary strictures, cirrhosis, and an increased risk of liver cancer.

Because PSC can be silent for long periods, early recognition and regular monitoring are essential. The information below summarizes what patients, families, and caregivers need to know.

Symptoms

Symptoms vary with disease stage. Some children are asymptomatic at diagnosis (detected during routine labs for IBD), while others present with severe cholestasis.

Common early symptoms

• Fatigue – persistent tiredness that does not improve with rest.
• Pruritus (itching) – often worse at night; caused by bile‑acid buildup.
• Upper right abdominal pain – dull or crampy pain near the liver.
• Jaundice – yellowing of the skin and whites of the eyes; indicates significant bile flow obstruction.
• Dark urine & pale stools – result of bilirubin excretion problems.
• Weight loss or poor growth – especially in younger children.

Symptoms that may signal disease progression

• Swelling of the abdomen (ascites) or legs (edema) due to low albumin.
• Repeated episodes of fever and right‑upper‑quadrant pain suggesting cholangitis.
• Unexplained bruising or bleeding (low clotting factors).
• Portal hypertension signs—variceal bleeding, splenomegaly.

Causes and Risk Factors

The exact cause of PSC remains unknown, but research points to a combination of genetic, immunologic, and environmental factors.

Genetic predisposition

• Family clustering is uncommon, yet certain HLA haplotypes (e.g., HLA‑DRB1*03, HLA‑B8) increase susceptibility.
• Genome‑wide association studies (GWAS) have identified risk loci near genes involved in immune regulation (e.g., *IL2RA*, *STAT3*).

Immune‑mediated mechanisms

• Auto‑immune attack on the bile‑duct epithelium is believed to drive inflammation.
• Strong association with IBD—about 70–80% of pediatric PSC patients have ulcerative colitis, suggesting shared immune pathways.

Environmental triggers

• Infections (especially intestinal bacteria) may initiate or exacerbate bile‑duct injury.
• Gut microbiome alterations (dysbiosis) have been observed in PSC, though causality is still being studied.

Risk factors for progression

• Co‑existing ulcerative colitis, especially extensive disease.
• Persistent elevated alkaline phosphatase (ALP) >1.5× upper limit of normal.
• Early onset of symptoms (<10 years old) and male sex.

Diagnosis

Diagnosing PSC requires a combination of clinical suspicion, laboratory testing, and imaging. A liver biopsy is reserved for uncertain cases.

Laboratory tests

• Liver enzymes: Elevated ALP, gamma‑glutamyl transferase (GGT), and mildly raised AST/ALT.
• Serum bilirubin: Usually normal early; rises as disease advances.
• Inflammatory markers: C‑reactive protein (CRP) may be high if associated IBD flares.
• Auto‑antibodies: p‑ANCA positive in ~70% of PSC patients; ANA and SMA may also be present.

Imaging studies

• Magnetic Resonance Cholangiopancreatography (MRCP): First‑line, non‑invasive test that visualizes intra‑ and extra‑hepatic bile‑duct strictures and beading.
• Endoscopic Retrograde Cholangiopancreatography (ERCP): Provides detailed images and allows therapeutic interventions (stenting, dilatation) but carries risk of pancreatitis—used when MRCP is inconclusive or treatment is needed.
• Ultrasound: Good for detecting liver size, fibrosis, and portal hypertension; often the initial screening tool.

Liver biopsy

Reserved for atypical presentations or when overlap with autoimmune hepatitis is suspected. Histology shows “onion‑skin” periductal fibrosis, cholestasis, and lymphocytic infiltrates.

Diagnostic criteria (simplified)

1. Persistent cholestatic liver enzyme pattern (ALP ≥ 1.5× ULN) for >6 months.
2. Imaging evidence of multifocal biliary strictures (MRCP/ERCP).
3. Exclusion of secondary causes (e.g., biliary stones, strictures from surgery, infections).

Treatment Options

There is currently no cure for PSC; therapy aims to slow progression, manage symptoms, and address complications.

Medications

• Ursodeoxycholic acid (UDCA): Widely used to improve bile flow and reduce ALP. Doses of 20–25 mg/kg/day are typical, though high‑dose regimens have not shown survival benefit and may increase risks (Mayo Clinic).
• Immunosuppressants: Generally ineffective for isolated PSC, but may be added if there is overlap with autoimmune hepatitis (e.g., azathioprine, 6‑mercaptopurine).
• Biologics for IBD: Anti‑TNF agents (infliximab, adalimumab) treat ulcerative colitis and may modestly improve liver enzyme trends (Cleveland Clinic).
• Pruritus control: Cholestyramine (2–4 g/day), rifampin, or sertraline. In refractory cases, experimental agents such as ileal bile‑acid transporter (IBAT) inhibitors are being studied.
• Vitamin supplementation: Fat‑soluble vitamins (A, D, E, K) due to malabsorption; vitamin D levels checked regularly.

Endoscopic and Radiologic Interventions

• Balloon dilatation or stenting: Relieves dominant biliary strictures that cause pain or cholangitis.
• ERCP with stone extraction: If pigmented stones develop.

Surgical options

• Liver transplantation: Indicated for end‑stage cirrhosis, recurrent cholangitis, or hepatocellular carcinoma. Post‑transplant survival rates exceed 80% at 5 years (UNOS data).

Lifestyle and supportive measures

• Balanced diet rich in protein and complex carbohydrates; limit saturated fats.
• Regular moderate exercise (30 min most days) to maintain weight and improve insulin sensitivity.
• Avoid alcohol and hepatotoxic medications (e.g., high‑dose acetaminophen, certain antibiotics).
• Vaccinations: Hepatitis A & B, influenza, pneumococcal—especially important after cirrhosis develops.

Living with Juvenile Primary Sclerosing Cholangitis

Managing a chronic liver condition in childhood or adolescence requires coordination among hepatology, gastroenterology, nutrition, and psychosocial services.

Daily management tips

• Medication adherence: Use pill organizers or smartphone reminders; keep a medication list for school or travel.
• Regular labs: Liver panel every 3–6 months, vitamin D every 6 months, and full blood count if on immunosuppressants.
• Monitor growth: Track height, weight, and BMI at each clinic visit; refer to a pediatric endocrinologist if growth falters.
• Skin care for itching: Cool compresses, fragrance‑free moisturizers, short fingernails, and avoiding hot showers.
• School accommodations: Provide a written plan for medication timing, bathroom access for urgent itching, and possible absences for medical appointments.
• Psychosocial support: Join support groups (e.g., PSC Foundation, local IBD/PSC clubs) to reduce isolation.

Follow‑up schedule

• Hepatology visit: Every 3–4 months (more frequent if labs are unstable).
• IBD clinic: Every 3 months or per gastroenterology recommendation.
• Imaging: Annual MRCP or ultrasound; sooner if new symptoms develop.
• Endoscopy: Colonoscopy every 1–2 years to surveil ulcerative colitis and screen for dysplasia.

Prevention

Because the root cause of PSC is not fully understood, primary prevention is limited. However, steps can reduce secondary risks and slow progression:

• Vaccinate against hepatitis A and B before liver disease advances.
• Maintain a healthy weight to avoid non‑alcoholic fatty liver disease (NAFLD) which can compound damage.
• Prompt treatment of bacterial cholangitis to prevent permanent duct injury.
• Adhere to IBD therapy—well‑controlled ulcerative colitis may lessen PSC activity.
• Limit exposure to hepatotoxic substances (alcohol, illicit drugs, certain herbal supplements).

Complications

If left unchecked, PSC can lead to serious health problems.

• Cirrhosis and liver failure: Most common long‑term outcome; may require transplantation.
• Dominant biliary strictures: Can cause recurrent cholangitis, pain, and jaundice.
• Portal hypertension: Results in varices, splenomegaly, and ascites.
• Cholangiocarcinoma (bile‑duct cancer): Lifetime risk in PSC is ~10–15% (higher than in IBD alone). Annual imaging and CA 19‑9 testing are recommended after age 10.
• Colorectal cancer: Co‑existing ulcerative colitis raises risk; colonoscopic surveillance is critical.
• Bone disease: Chronic cholestasis leads to osteoporosis; DEXA scans every 2–3 years are advised.
• Fat‑soluble vitamin deficiencies: May cause bleeding tendencies (vitamin K) or night blindness (vitamin A).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, American Liver Foundation, United Network for Organ Sharing (UNOS), peer‑reviewed journals (Hepatology, Gastroenterology). Information is for educational purposes and does not replace professional medical advice.

```